Trial Profile
Open-label, Uncontrolled, Dose-escalation Study of ONO-7475 Given as Monotherapy and Combinations With ONO-4538 in Patients With Advanced or Metastatic Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Oct 2023
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Tamnorzatinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Ono Pharmaceutical
- 02 Oct 2023 Status changed from suspended to completed.
- 19 Dec 2021 Status changed from recruiting to suspended. Reason the study was stopped: The enrollment was temporarily completed.
- 19 May 2021 Planned End Date changed from 1 Apr 2021 to 1 Apr 2023.